For the treatment of CAP, in which patient types do you think ceftaroline is the most valuable and where do you fit ceftaroline into the current treatment pathway?
In this video, Prof. Matteo Bassetti describes the treatment of CAP, including in which patient types ceftaroline fosamil is most valuable and where ceftaroline fosamil fits into the current treatment pathway.
How does non-response to initial treatment affect
outcomes in CAP?
This video describes how nonresponse to initial treatment affects the outcomes in CAP.
How do ceftaroline characteristics compare with other agents currently being used in CAP?
This video describes how ceftaroline fosamil characteristics compare to other agents that are currently being used for the treatment of CAP.
What is the efficacy of ceftaroline in high-risk patients, such as those with comorbidities, in Phase III CAP trials (FOCUS 1 and 2 and Asia CAP)
In this video, Prof. Tobias Welte answers the question 'What is the efficacy of ceftaroline fosamil in high-risk patients, such as those with comorbidities, in Phase III CAP trials (FOCUS 1 and FOCUS 2, and ASIA CAP)?'
ZINFORO® in patients with post-influenza bacterial
This video presents the case study of a patient on ceftaroline fosamil treatment: Patient Case Animation – Case 1 (CAP).
How does the proportion of adverse events in ceftaroline clinical trials compare to real-world experience?
This video provides information on how the proportion of AEs in ceftaroline fosamil clinical trials compare to the real-world experience.
Prof. Matthew Dryden and Prof. Tobias Welte describes clinical trials versus the real-world experience.
ZINFORO® binds to all 6 PBPs that have been identified in S. pneumoniae (PBP1A, 1B, 2x, 2A/B and 3)
This video describes the MoA of ZINFORO® (ceftaroline fosamil) indicated in the treatment of CAP and cSSTI.
ZINFORO® in patients with multiple comorbidities
This video presents the case study of a patient on ceftaroline fosamil treatment: Patient Case Animation – Case 3 (CAP).
ZINFORO® is recommended by official practice guidelines (IDSA and ATS)
This video focusses on the IDSA publication of ZINFORO®.
ZINFORO® provides swift, decisive action against CAP, with a rapid response at Day 4
This video describes the clinical efficacy of ZINFORO® in CAP.
ZINFORO® provides rapid and potent activity against key causative pathogens in CAP and cSSTI
This video provides information on how ZINFORO® delivers a rapid and potent activity against the key causative pathogens in CAP.
ZINFORO® provides clinical stability for CABP treatment
This video highlights ceftaroline fosamil, which provides clinical stability over ceftriaxone at Day 4 for CABP treatment.
ATS, American Thoracic Society; AE, adverse event; CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infection; FOCUS, ceFtarOline Community-acquired pneUmonia trial versuS ceftriaxone in hospitalized patients; IDSA, Infectious Diseases Society of America; MoA, mechanism of action.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.